Literature DB >> 15863637

Exhaled NO may predict the decline in lung function in bronchiolitis obliterans syndrome.

O Brugière1, G Thabut, H Mal, A Marceau, G Dauriat, R Marrash-Chahla, Y Castier, G Lesèche, M Colombat, M Fournier.   

Abstract

Bronchiolitis obliterans syndrome (BOS) remains the leading cause of morbidity/mortality following lung transplantation. In recipients with BOS, markers predicting the decline in lung function are needed. The aim of this longitudinal study was to determine whether exhaled nitric oxide fraction (FeNO) measurements provide useful information for discriminating patients with unstable BOS from those with stable BOS. During a 14-month period, 145 FeNO measurements were performed in 50 lung transplant recipients. Among them, 16 recipients with BOS (32 FeNO measurements) were analysed. For each FeNO measurement, the patients were classified into three groups according to the decline in forced expiratory volume in one second (FEV1) within the following 6 months: 1) stable BOS free; 2) stable BOS (decline in FEV1 of <5%); and 3) unstable BOS (decline in FEV1 of > or =15%). The mean FeNO in patients with unstable BOS was significantly increased compared with that in stable BOS-free patients (18.4+/-5.7 versus 9.7+/-3.7 ppb) and that in patients with stable BOS (18.4+/-5.7 versus 9.7+/-3.3 ppb). The present findings suggest that, in patients with bronchiolitis obliterans syndrome, a raised exhaled nitric oxide fraction may predict the development of worrisome functional impairment during long-term follow-up.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863637     DOI: 10.1183/09031936.05.00057004

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

Review 1.  Exhaled nitric oxide measurements: clinical application and interpretation.

Authors:  D R Taylor; M W Pijnenburg; A D Smith; J C De Jongste
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

2.  Serial monitoring of exhaled nitric oxide in lung transplant recipients.

Authors:  Mohamed A Gashouta; Christian A Merlo; Matthew R Pipeling; John F McDyer; J W Awori Hayanga; Jonathan B Orens; Reda E Girgis
Journal:  J Heart Lung Transplant       Date:  2014-11-06       Impact factor: 10.247

Review 3.  Clinical application of exhaled nitric oxide measurement in pediatric lung diseases.

Authors:  Angelo Manna; Carlo Caffarelli; Margherita Varini; Carlotta Povesi Dascola; Silvia Montella; Marco Maglione; Francesco Sperlì; Francesca Santamaria
Journal:  Ital J Pediatr       Date:  2012-12-31       Impact factor: 2.638

Review 4.  Chronic allograft dysfunction.

Authors:  Christiane Knoop; Marc Estenne
Journal:  Clin Chest Med       Date:  2011-06       Impact factor: 2.878

5.  Exhaled nitric oxide in diagnosis and management of respiratory diseases.

Authors:  Abdullah A Abba
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

6.  Application of nitric oxide measurements in clinical conditions beyond asthma.

Authors:  Andrei Malinovschi; Dora Ludviksdottir; Ellen Tufvesson; Giovanni Rolla; Leif Bjermer; Kjell Alving; Zuzana Diamant
Journal:  Eur Clin Respir J       Date:  2015-08-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.